Adherium Ltd. · ASX:ADR
Adherium — Investor Presentation (October 2025)
26 slides from Adherium's investor presentation, October 2025
Slide 1: A New Frontier In Respiratory Care
ASX: ADR A New Frontier In Respiratory Care October 2025
Slide 2: Disclaimer and Forward-Looking Statement
Disclaimer and Forward-Looking Statement The material contained herein is of a general nature & has only been prepared as a. the possible delays in & the outcome of product development a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating A
Slide 3: Dr. J. Allen Meadows, Dawn Bitz, Keven Gessner
Dr. J. Allen Meadows Dawn Bitz Keven Gessner MD and ACAAI, Executive Director Of Adherium, Chief Executive Officer Adherium, BOD and Senior Executive Advocacy and Governmental Affairs Advisor Adheriu m | A new frontier in respiratory c are 3
Slide 4: Americans live with 40M chronic respiratory disease
Americans live with 40M chronic respiratory disease Non-adherence with medications is a primary cause of avoidable hospitalisations, emergency department visits and billions in costs to the healthcare system
Slide 5: What are Asthma and COPD?
What are Asthma and Asthma COPD? • Airways get swollen and tight • Makes it hard to breathe (wheezing, coughing, chest tightness) While asthma and COPD • May be sensitive to triggers like allergies, exercise, or colds are different conditions, • Often starts in children and can grow into chronic adu
Slide 6: In the United States, COPD costs $59.6B with an average cost of ~$18k per severe patient
In the United States, COPD costs $59.6B with an average cost Prescribed Pharma of ~$18k per severe 28% Hospital 29% Inpatient patient1,2 Nearly half of costs are COPD direct tied to hospitalisations cost breakdown and ED visits by type3 General 10% 10% Admin Ambulatory 13% 10% Nursing Emergency Care
Slide 7: COPD flare ups (exacerbations) spiral after the first episode
COPD flare ups (exacerbations) spiral after the first episode4 One flare up can reduce significantly reduce lung function, setting off a chain of flare ups, further lung decline, and costly hospitalisations. Stopping the first flare up can prevent many future events and avoid multiple costly hospita
Slide 8: Flare ups irreversibly reduce lung function and nearly 4x the risk of cardiovascular events
Flare ups irreversibly COPD reduce lung function Worsening Symptoms and nearly 4x the Increased breathlessness and frequent productive cough = higher risk of exacerbations risk of cardiovascular events, leading to +79% risk of death COPD Cardiopulmonary Flare up/Exacerbations Events and COPD Exacerb
Slide 9: If COPD patients are 60% or greater adherent, their risk of hospitalisation drops ~50%
If COPD patients are Reduction to the Risk of Hospitalisations Based on Levels of Adherence in COPD 60% or greater adherent to their 80-100% medications, their risk Adherence 51% of hospitalisation drops ~50%12 60-80% Adherence Most patients demonstrate 48% adherence of 20% or less 40-60% Adherence
Slide 10: The iCARE respiratory care program
The iCARE respiratory care program First-of-its-kind program demonstrating how continuous digital monitoring and care can drive patient adherence and lower costs due to avoidable hospitalisations and emergency department visits
Slide 11: About Intermountain Health (IMH)
About Intermountain Health (IMH) IMH’s goal is to advance its triple aim: improving patient lives, enhancing health outcomes, and lowering healthcare costs Leading US health system with 33 hospitals and 385 clinics Located in Utah, Idaho, Colorado, Nevada, Kansas and Montana Over 250,000 respiratory
Slide 12: The iCARE clinical program, featuring Adherium Technology
The iCARE clinical program, featuring Adherium Technology Adherium connected inhalers provided data, enhanced oversight, tracked use, and uncovered key insights (e.g., improvements to technique, overreliance of rescue meds) Full Stack, HCP decision Secure Precision Insights support tools Technology
Slide 13: Landmark independent program demonstrating robust clinical outcomes
Landmark independent program demonstrating robust clinical outcomes 848 patients tracked with some on for over 14-months+ (program ongoing) Physician-driven enrollment – very broad selection criteria Independent clinical care program, no vendor-paid monitoring or incentives Designed and driven by In
Slide 14: iCARE patients demonstrated 67% adherence in COPD and 64% in asthma
iCARE patients demonstrated 67% adherence in COPD and 64% in asthma 1.5-3x industry standard norms of 20-40% Improved adherence compared to reported “norms” 13-16 70% 67% 60% 64% 50% 40% 30% 20% 22% 20% Benchmark 10 % norm adherence 0% iCARE adherence Asthma COPD Adheriu m | A new frontier in respir
Slide 15: 1/3 >80% adherence, 67% adherence
These adherence levels Reduction to the Risk of Hospitalisations strongly suggest that it Based on Levels of Adherence in COPD could cut hospitalisations 80-100% by half for patients with Adherence 51% COPD 60-80% Nearly one-third of iCARE patients Adherence 48% sustained >80% adherence with an over
Slide 16: Sustained adherence over 14+ months
Sustained adherence over 14+ months Where others see drop-off, iCARE patients stay the course – even amongst 70–80-year-olds Long-term adherence levels 80% 70% 60% 64% 67% 50% 40% 30% 20% 28% 10 % 22% 0% Foster Study17 iCARE13 Mannino Study18 iCARE13 Asthma Asthma COPD COPD at at 6 months at 14 mont
Slide 17: In summary, iCARE demonstrated
In summary, iCARE demonstrated A significant Adherence levels Persistent adherence, Even higher improvement in > 60%, associated maintained over persistence amongst adherence (1.5-3x with a 50% reduction 14 months older, most costly industry norms) in hospitalisation risk patients Adheriu m | A n ew
Slide 18: US Payers Could Save Significant Costs
US Payers Could Save Significant Costs
Slide 19: Adherence drives savings: IMH's Payer arm Select Health
Adherence drives savings: IMH’s Payer arm “Select Health” could unlock significant savings of nearly $60M % of COPD patients COPD patients 50% annual cost savings Revenue onboarded enrolled (illustrative) hospitalisations / ED visits @ $70 pp/mo 5% participation 3.3K $30M $3M 10% participation 6.6K
Slide 20: Cigna, national US payer, could save nearly $1B in direct costs
Cigna, national US payer, could save nearly $1B in direct costs with just 10% of its COPD patients; unlocking value for Adherium % of COPD patients COPD patients 50% annual Revenue onboarded enrolled (illustrative) cost savings18 @ $70 pp/mo 5% participation 53K $473M $44M 10% participation 105K $94
Slide 21: Adherium is the only payer-ready respiratory platform
Adherium is the only payer-ready respiratory platform Payers fund what’s proven, covers most patients, and works in the real world Proven Coverage Capability FDA-cleared Works with Tracks adherence most inhalers Real-world Tracks technique evidence at scale For both asthma and COPD Adheriu m | A new
Slide 22: Operational Proof at the Practice Level
Operational Proof at the Practice Level Massive payer upside starts with today’s proof: a fee-for-service model building a scalable playbook
Slide 23: From zero to 4,000: strong momentum unlocked by practice partnerships and hospital programs
From zero to 4,000: strong momentum unlocked by practice partnerships and hospital programs 4,00 0 • Call Center (launched August 2025): Scaling to 4k+ patients by year end streamlined lead processing at scale 3,00 0 • September finished +109% higher than average prior month 2,00 0 • Backlog of 70k
Slide 24: Key takeaways
Key takeaways IMH’s iCare program These adherence levels Reductions in costs Adherium now has the demonstrates that are likely to drive could save payers technology and proof gathering data improved patient significant amounts to engage and scale insights with outcomes by of money and with US provid
Slide 25: Thank You
Thank You
Slide 26: References
References 1. Zafari Z et al. Projecting Long-term Health and Economic Burden of COPD in the United States. Chest. 2021 Apr;159(4):1400-1410 2. Wallace AE, Kaila S, Bayer V, Shaikh A, Shinde MU, Willey VJ, Napier MB, Singer JR. Health Care Resource Utilization and Exac erbation Rates in Patients wit